A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.
To continue reading click here
